Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank14
3Y CAGR-17.9%
5Y CAGR-11.1%
Year-over-Year Change
Research and development spending
3Y CAGR
-17.9%/yr
vs +6.5%/yr prior
5Y CAGR
-11.1%/yr
Recent deceleration
Acceleration
-24.4pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $33.30M | +42.4% |
| 2024 | $23.38M | -4.7% |
| 2023 | $24.52M | -59.3% |
| 2022 | $60.27M | -7.6% |
| 2021 | $65.24M | +8.5% |
| 2020 | $60.10M | +13.6% |
| 2019 | $52.88M | +12.8% |
| 2018 | $46.90M | +1.4% |
| 2017 | $46.27M | -27.1% |
| 2016 | $63.45M | - |